Literature DB >> 20697550

Hemophilia: an amazing 35-year journey from the depths of HIV to the threshold of cure.

Gilbert C White1.   

Abstract

Methods developed in the early 1970s to highly purify factor VIII (FVIII) from the plasma of large numbers of blood donors led, for the first time, to concentrates of FVIII that enabled hemophiliac to self-treat, providing independence and opening the way to safe surgery and other treatments. But, with the introduction of blood-borne viruses such as HIV-1 and hepatitis C viruses into the blood supply, these concentrates also transmitted HIV and hepatitis to a high percentage of hemophiliacs. Nevertheless, from the depths of the AIDS epidemic in hemophilia came extraordinary scientific advances that led to recombinant FVIII, the identification of HIV as the agent causing AIDS, the eventual development of effective treatments for AIDS, gene transfer approaches using lentiviruses, and treatments for hepatitis C. All of these have improved the lives of current and future hemophiliacs and have brought us to the threshold of a cure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697550      PMCID: PMC2917149     

Source DB:  PubMed          Journal:  Trans Am Clin Climatol Assoc        ISSN: 0065-7778


  44 in total

1.  Characterization of the human factor VIII gene.

Authors:  J Gitschier; W I Wood; T M Goralka; K L Wion; E Y Chen; D H Eaton; G A Vehar; D J Capon; R M Lawn
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

2.  Structure of human factor VIII.

Authors:  G A Vehar; B Keyt; D Eaton; H Rodriguez; D P O'Brien; F Rotblat; H Oppermann; R Keck; W I Wood; R N Harkins; E G Tuddenham; R M Lawn; D J Capon
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

3.  Molecular cloning of a cDNA encoding human antihaemophilic factor.

Authors:  J J Toole; J L Knopf; J M Wozney; L A Sultzman; J L Buecker; D D Pittman; R J Kaufman; E Brown; C Shoemaker; E C Orr
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

4.  Pneumocystis carinii pneumonia among persons with hemophilia A.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1982-07-16       Impact factor: 17.586

5.  Expression of active human factor VIII from recombinant DNA clones.

Authors:  W I Wood; D J Capon; C C Simonsen; D L Eaton; J Gitschier; B Keyt; P H Seeburg; D H Smith; P Hollingshead; K L Wion; E Delwart; E G Tuddenham; G A Vehar; R M Lawn
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

6.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

7.  Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines.

Authors:  L Montagnier; J Gruest; S Chamaret; C Dauguet; C Axler; D Guétard; M T Nugeyre; F Barré-Sinoussi; J C Chermann; J B Brunet
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

8.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS.

Authors:  J Schüpbach; M Popovic; R V Gilden; M A Gonda; M G Sarngadharan; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  5 in total

1.  Animal models: Dogged pursuit.

Authors:  Emily Sohn
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 2.  Novel therapies and current clinical progress in hemophilia A.

Authors:  Pauline Balkaransingh; Guy Young
Journal:  Ther Adv Hematol       Date:  2017-12-28

Review 3.  Mortality in congenital hemophilia A - a systematic literature review.

Authors:  Charles R M Hay; Francis Nissen; Steven W Pipe
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

Review 4.  Emerging therapies for hemophilia: controversies and unanswered questions.

Authors:  Valder R Arruda; Bhavya S Doshi; Benjamin J Samelson-Jones
Journal:  F1000Res       Date:  2018-04-24

5.  Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.

Authors:  Laura A Schieve; Vanessa R Byams; Brandi Dupervil; Meredith A Oakley; Connie H Miller; J Michael Soucie; Karon Abe; Christopher J Bean; W Craig Hooper
Journal:  MMWR Surveill Summ       Date:  2020-09-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.